2018
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract
2015
Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?
Narayanan S, Kunz P. Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors? International Journal Of Endocrine Oncology 2015, 2: 13-20. DOI: 10.2217/ije.14.37.Peer-Reviewed Original ResearchManagement of NETsNeuroendocrine tumorsCytotoxic chemotherapySystemic cytotoxic chemotherapyCurrent treatment guidelinesPresent clinical trialGroup of biologicallyBiologic therapyTreatment guidelinesClinical trialsHeterogeneous neoplasmsChemotherapyDegree of responsivenessTherapyTumorsNeoplasmsTrialsBiologics